PharmaNet Pursues Strategic Alternatives, Possible Sale

Friday, December 19, 2008 11:57 AM

Troubled contract research organization (CRO) PharmaNet Development Group announced Thursday that it is working with a financial advisor from USB Investment Bank to explore strategic alternatives, including the potential sale of the company.

This move follows a year of struggles for the Princeton, N.J.-based CRO. Since the start of 2008, PharmaNet’s share price has plunged 97% from $39.19 in January to $1.01 in early morning trading Friday, and, in September, PharmaNet cut its full-year revenue forecast more than $30 million.

“The board of directors and management believe that pursuing strategic alternatives will maximize shareholder value,” said PharmaNet president and CEO Jeffrey McMullen in a company statement.

The CRO has received a several non-binding letters of interest regarding the sale of the company from non-competitors, according to the company release, but the company will not comment further on the process until a definitive strategic decision or agreement is made.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

May 20

IRB consolidation trend continues, as private equity firm Audax buys majority stake in Chesapeake

Quintiles, Merck Serono ink exclusive partnership

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

INC Research, PPD, inVentiv named top CROs
Yet most CROs slipping in ability to manage site relationships

R&D cuts by sponsors spur more collaboration, innovation
New strategies share pipeline activity costs

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

20 innovators changing the face of the clinical trials industry
The CenterWatch Monthly honors individuals, teams and companies for their forward-thinking ideas and their ability to implement them.

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs